Targeting MYC: From understanding its biology to drug discovery

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The MYC oncogene is frequently activated in human cancers, making it a critical therapeutic target.
• Direct inhibition of MYC is challenging due to its disordered structure and lack of a defined binding site.
• Recent advances in structural biology and computational tools enable novel indirect targeting strategies.

Purpose of the Study:

• To review small molecules developed for indirect MYC inhibition strategies.
• To discuss emerging targets for MYC-directed cancer therapies.

Main Methods:

• Review of literature on small molecules targeting MYC.
• Analysis of strategies including MYC guanine quadruplex stabilization, BET factor inhibition, and MYC:MAX heterodimer disruption.
• Discussion of novel protein-level targets for indirect MYC inhibition.

Main Results:

• Several small molecules have been developed for clinical applications targeting MYC indirectly.
• Strategies include stabilizing the MYC guanine quadruplex, inhibiting BRD4, and disrupting the MYC:MAX complex.
• Novel protein targets for indirect MYC inhibition have been identified.

Conclusions:

• Indirect targeting strategies offer viable clinical approaches for MYC-driven cancers.
• The development of small molecules for these strategies is advancing cancer therapeutics.
• Continued research into novel targets will further enhance MYC-directed cancer interventions.